急性髓系白血病FANCG基因表达的研究

本研究探讨FANCG基因表达与成人散发性急性髓系白血病（AML）的相关性。采用SYBR GreenⅠ实时荧光定量PCR方法检测54例AML初诊患者、46例AML完全缓解（CR）患者及36例对照样本骨髓中单个核细胞FANCG基因表达的情况，以β-Actin基因作为内参，根据相对定量公式2^-△△C_T计算AML初诊患者与对照样本、AML初诊患者与AMLCR患者、AMLCR患者与对照样本FANCG基因表达差异的倍数。结果表明，AML初诊组FANCGmRNA的相对表达量为0．56±0．27，AMLCR组为0．75±0．54，对照组为0．85±0．45；AML初诊组FANCGmRNA的表达量较对照组和AMLCR组明显降低（P〈0．05）；AMLCR组FANCGmRNA的表达量与对照组比较无统计学差异。结论：FANCG基因在初诊AML患者中表达降低，AMLCR患者的FANCG基因表达与对照组无明显差异，提示FANCG基因可能与AML的发病有相关性，同时在判断AML的化疗疗效方面具有一定的临床参考价值。

Expression of FANCG Gene in Acute Myeloid Leukemia

This study was purposed to investigate the relationship between expression of the FANCG gene and adult sporadic acute myeloid leukemia（ AML）, real-time PCR with SYBR Green Ⅰ technique was used for detecting FANCG gene expression level in bone marrow mononuclear cells of 54 newly diagnosed AML patients, 46 AML patients in complete remission （CR） and 36 control samples, β-actin gene was used as internal reference. Relative changes of FANCG gene expression level were detected by 2^-△△C_T method in newly diagnosed AML patients and control samples, in newly diagnosed AML and patient in CR, as well as in AML patients in CR and control samples. The results showed that the relative expression level of FANCG mRNA was 0.56 ± 0.27 in newly diagnosed group, 0.75 ± 0.54 in AML CR group, and 0. 85± 0.45 in control group. The expression level of FANCG mRNA in newly diagnosed group was significantly lower than that in control and AML CR groups （ P 〈 0.05 ）. There was no statistically significant defference in comparison of AML CR group with the control group （ P 〉 0.05 ）. It is concluded that the expression of FANCG gene decrease in the newly diagnosed AML patients. There is no significant difference between AML CR group and cntrol group, which indicated that FANCG gene may be related with the onset and the prognosis of AML, and may provide a clinical value for evaluating effect of chemotherapy.